Ashley Gallagher is an assistant editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
Report: Gen Z Knows Least About HIV Compared to Older Generations
September 20th 2023Investigators of the GLAAD and Gilead COMPASS Initiative survey tracked the progress against HIV stigma, the transmission and prevention of HIV, and the attitudes and knowledge of those living with HIV in the United States.
Read More
Cancer Diagnoses Significantly Decreased in First Few Months of COVID-19 Pandemic
September 14th 2023Investigators found an approximately 23% decrease in overall cancer incidence in April 2020, specifically for breast, colon, rectal, head and neck cancers, as well as melanoma and endocrine cancer diagnoses.
Read More
CDC’s ACIP Votes in Favor of Universal Recommendation for 2023-2024 Monovalent COVID-19 Vaccines
September 13th 2023The CDC emphasized the need for protein-based vaccine options in endorsing a vote by the Advisory Committee on Immunization Practices for the universal recommendation of the 2023-2024 monovalent, XBB containing COVID-19 vaccines.
Read More
Cognitive Training Programs Have No Long-Term Benefit for Children Born Very Preterm
September 13th 2023Children born at 24- through 34-weeks’ gestation could have neurobehavioral problems and developmental dysfunctions, including language, executive function, attention, and behavioral disorders.
Read More
Resistance Mechanisms, Host Interactions Remain Elusive for Clostridioides difficile Research
September 12th 2023Investigators said that understanding virulence factors, resistance mechanisms, and host interactions can help establish the development of novel therapeutics for Clostridioides difficile.
Read More
Intravenous Immunoglobulin Can Induce Biological Response Due to Anti-Inflammatory Mechanisms
September 11th 2023Research into the mechanisms of intravenous immunoglobulin is often challenging due to the complexity of polyclonal preparations, including diversity, repertoires, blocking, or anti-idiotypic antibodies.
Read More
Study: African Ancestry Associated With Aggressive Breast Cancer Subtypes
September 6th 2023African ancestry was associated with higher odds of estrogen receptor-negative and triple-negative breast cancer; however, social environments were strongly associated with the survival of Black individuals with breast cancer.
Read More
Study: Blood Cancer Treatment Found to Kill Latent HIV-Infected Cells, Possible New Treatment
September 6th 2023Although antiretroviral therapies are the standard of care treatment for those with HIV, the drugs cannot target latent infections; however, venetoclax, a blood cancer treatment, shows promise.
Read More
COVID-19 Vaccination Reduces Serious Disease, But Lymphoma Patients Continue to Be Vulnerable
August 31st 2023Patients with lymphoma can be immunocompromised due to their disease, anti-cancer therapy, and concomitant immunosuppressive treatments, which make them more vulnerable to developing a COVID-19 infection.
Read More
Supplemental Biologics License Application Submitted to Expand Approval of Rybrevant for NSCLC
August 29th 2023The supplemental biologics license application for amivantamab-vmjw (Rybrevant) is supported by data from the phase 3 PAPILLON trial, evaluating the efficacy and safety of the drug in combination with chemotherapy for those with non–small cell lung cancer.
Read More